QQQ   358.44 (+0.12%)
AAPL   171.18 (+0.29%)
MSFT   316.03 (+0.76%)
META   301.20 (-0.91%)
GOOGL   130.81 (-1.13%)
AMZN   127.00 (+0.81%)
TSLA   249.59 (+1.30%)
NVDA   435.55 (+1.08%)
NIO   9.01 (+1.12%)
BABA   86.83 (+1.51%)
AMD   103.63 (+0.85%)
T   14.98 (-0.20%)
F   12.41 (-1.19%)
MU   68.19 (+4.59%)
CGC   0.79 (-3.02%)
GE   110.77 (-1.40%)
DIS   80.89 (+0.95%)
AMC   7.95 (+2.05%)
PFE   33.09 (+3.12%)
PYPL   58.33 (+0.26%)
NFLX   376.80 (+0.12%)
QQQ   358.44 (+0.12%)
AAPL   171.18 (+0.29%)
MSFT   316.03 (+0.76%)
META   301.20 (-0.91%)
GOOGL   130.81 (-1.13%)
AMZN   127.00 (+0.81%)
TSLA   249.59 (+1.30%)
NVDA   435.55 (+1.08%)
NIO   9.01 (+1.12%)
BABA   86.83 (+1.51%)
AMD   103.63 (+0.85%)
T   14.98 (-0.20%)
F   12.41 (-1.19%)
MU   68.19 (+4.59%)
CGC   0.79 (-3.02%)
GE   110.77 (-1.40%)
DIS   80.89 (+0.95%)
AMC   7.95 (+2.05%)
PFE   33.09 (+3.12%)
PYPL   58.33 (+0.26%)
NFLX   376.80 (+0.12%)
QQQ   358.44 (+0.12%)
AAPL   171.18 (+0.29%)
MSFT   316.03 (+0.76%)
META   301.20 (-0.91%)
GOOGL   130.81 (-1.13%)
AMZN   127.00 (+0.81%)
TSLA   249.59 (+1.30%)
NVDA   435.55 (+1.08%)
NIO   9.01 (+1.12%)
BABA   86.83 (+1.51%)
AMD   103.63 (+0.85%)
T   14.98 (-0.20%)
F   12.41 (-1.19%)
MU   68.19 (+4.59%)
CGC   0.79 (-3.02%)
GE   110.77 (-1.40%)
DIS   80.89 (+0.95%)
AMC   7.95 (+2.05%)
PFE   33.09 (+3.12%)
PYPL   58.33 (+0.26%)
NFLX   376.80 (+0.12%)
QQQ   358.44 (+0.12%)
AAPL   171.18 (+0.29%)
MSFT   316.03 (+0.76%)
META   301.20 (-0.91%)
GOOGL   130.81 (-1.13%)
AMZN   127.00 (+0.81%)
TSLA   249.59 (+1.30%)
NVDA   435.55 (+1.08%)
NIO   9.01 (+1.12%)
BABA   86.83 (+1.51%)
AMD   103.63 (+0.85%)
T   14.98 (-0.20%)
F   12.41 (-1.19%)
MU   68.19 (+4.59%)
CGC   0.79 (-3.02%)
GE   110.77 (-1.40%)
DIS   80.89 (+0.95%)
AMC   7.95 (+2.05%)
PFE   33.09 (+3.12%)
PYPL   58.33 (+0.26%)
NFLX   376.80 (+0.12%)

Poseida Therapeutics (PSTX) Stock Forecast, Price & News

$2.34
-0.11 (-4.49%)
(As of 03:10 PM ET)
Compare
Today's Range
$2.28
$2.52
50-Day Range
$1.62
$2.79
52-Week Range
$1.54
$8.82
Volume
307,183 shs
Average Volume
814,292 shs
Market Capitalization
$203.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.33

Poseida Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
499.7% Upside
$14.33 Price Target
Short Interest
Healthy
6.40% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.93
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.46) to ($1.82) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.41 out of 5 stars

Medical Sector

244th out of 972 stocks

Biological Products, Except Diagnostic Industry

35th out of 158 stocks


PSTX stock logo

About Poseida Therapeutics (NASDAQ:PSTX) Stock

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-101, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101, a liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; and P-PAH-101, a liver-directed gene therapy for the in vivo treatment of phenylketonuria. Poseida Therapeutics, Inc. has a research collaboration and license agreement with Takeda Pharmaceuticals USA, Inc., F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.

PSTX Price History

PSTX Stock News Headlines

Successful Options Trading Begins With…
Options trading expert Wendy Kirkland’s free guide reveals the options trading principles that are as easy to implement as they are to learn and how using them could earn you thousands in extra income each month!
Successful Options Trading Begins With…
Options trading expert Wendy Kirkland’s free guide reveals the options trading principles that are as easy to implement as they are to learn and how using them could earn you thousands in extra income each month!
Poseida Therapeutics (PSTX) Gets a Buy from BTIG
See More Headlines
Receive PSTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Poseida Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PSTX Company Calendar

Last Earnings
8/08/2023
Today
9/29/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PSTX
Fax
N/A
Employees
348
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$14.33
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+512.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-64,000,000.00
Pretax Margin
-18.29%

Debt

Sales & Book Value

Annual Sales
$130.49 million
Book Value
$2.18 per share

Miscellaneous

Free Float
85,091,000
Market Cap
$203.39 million
Optionable
Not Optionable
Beta
0.05
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Mark J. Gergen J.D. (Age 60)
    Pres, CEO & Chairman
    Comp: $920.74k
  • Mr. Harry J. Leonhardt Esq. (Age 66)
    J.D., Gen. Counsel, Chief Compliance Officer & Corp. Sec.
    Comp: $630.23k
  • Mr. Brent Warner (Age 39)
    Pres of Gene Therapy
    Comp: $835.93k
  • Ms. Johanna M. Mylet CPA (Age 36)
    Chief Financial Officer
  • Mr. Loren Wagner
    Sr. VP of Global Operations
  • Ms. Kristin Martin
    Chief People & Admin. Officer
  • Sarah Thailing
    Sr. Director of Corp. Communications & IR
  • Dr. Devon J. Shedlock Ph.D.
    Chief Scientific Officer of Cell Therapy
  • Ms. Lisa Portale
    Sr. VP of Regulatory Affairs
  • Dr. Jeffrey W. Winkelman J.D.
    Ph.D., Sr. VP & Chief Patent Counsel













PSTX Stock - Frequently Asked Questions

Should I buy or sell Poseida Therapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Poseida Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PSTX shares.
View PSTX analyst ratings
or view top-rated stocks.

What is Poseida Therapeutics' stock price forecast for 2023?

3 equities research analysts have issued 12 month price objectives for Poseida Therapeutics' stock. Their PSTX share price forecasts range from $14.00 to $15.00. On average, they expect the company's share price to reach $14.33 in the next twelve months. This suggests a possible upside of 512.5% from the stock's current price.
View analysts price targets for PSTX
or view top-rated stocks among Wall Street analysts.

How have PSTX shares performed in 2023?

Poseida Therapeutics' stock was trading at $5.30 on January 1st, 2023. Since then, PSTX stock has decreased by 55.8% and is now trading at $2.34.
View the best growth stocks for 2023 here
.

When is Poseida Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our PSTX earnings forecast
.

How were Poseida Therapeutics' earnings last quarter?

Poseida Therapeutics, Inc. (NASDAQ:PSTX) announced its earnings results on Tuesday, August, 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.53) by $0.21. The firm had revenue of $20.01 million for the quarter, compared to analyst estimates of $10 million. Poseida Therapeutics had a negative trailing twelve-month return on equity of 16.77% and a negative net margin of 18.64%.

What ETF holds Poseida Therapeutics' stock ?

Kelly CRISPR & Gene Editing Technology ETF holds 49,027 shares of PSTX stock, representing 3.32% of its portfolio.

What other stocks do shareholders of Poseida Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Poseida Therapeutics investors own include Moderna (MRNA), Advanced Micro Devices (AMD), AngloGold Ashanti (AU), Micron Technology (MU), Eaton (ETN), Corning (GLW), OPKO Health (OPK), Overstock.com (OSTK), Sorrento Therapeutics (SRNE) and SSR Mining (SSRM).

When did Poseida Therapeutics IPO?

(PSTX) raised $150 million in an initial public offering (IPO) on Friday, July 10th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Piper Sandler and William Blair served as the underwriters for the IPO.

What is Poseida Therapeutics' stock symbol?

Poseida Therapeutics trades on the NASDAQ under the ticker symbol "PSTX."

How do I buy shares of Poseida Therapeutics?

Shares of PSTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Poseida Therapeutics' stock price today?

One share of PSTX stock can currently be purchased for approximately $2.34.

How much money does Poseida Therapeutics make?

Poseida Therapeutics (NASDAQ:PSTX) has a market capitalization of $203.39 million and generates $130.49 million in revenue each year. The company earns $-64,000,000.00 in net income (profit) each year or ($0.24) on an earnings per share basis.

How many employees does Poseida Therapeutics have?

The company employs 348 workers across the globe.

How can I contact Poseida Therapeutics?

Poseida Therapeutics' mailing address is 9390 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.poseida.com. The company can be reached via phone at 858-779-3100 or via email at ir@poseida.com.

This page (NASDAQ:PSTX) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -